Functional down-regulation of beta1 and beta2 integrins of lamina propria lymphocytes (LPL) and tumor-infiltrating lymphocytes (TIL) in colorectal cancer patients
- PMID: 10458690
- DOI: 10.1007/s10434-999-0500-y
Functional down-regulation of beta1 and beta2 integrins of lamina propria lymphocytes (LPL) and tumor-infiltrating lymphocytes (TIL) in colorectal cancer patients
Abstract
Integrins play an important role in various lymphocyte functions. In this study, we isolated lamina propria lymphocytes (LPL) and tumor-infiltrating lymphocytes (TIL) from normal and malignant tissues in patients with colorectal cancer, and examined the expression of beta1 and beta2 integrins on these lymphocytes quantitatively with two-color flow cytometry. Both LPL and TIL expressed a lower level of common beta1 chain (CD29) in CD4 and CD8 subpopulations than did peripheral blood lymphocytes (PBL). Among the associated alpha chains, the expression levels of alpha1 (CD49a) and alpha2 (CD49b) were slightly higher, whereas those of alpha4 (CD49d) and alpha6 (CD49f) were markedly reduced in LPL and TIL. No significant differences were observed in expressions of any alpha1 integrin chains between these two lymphocytes populations. Similarly, both alphaL (CD11a) and beta2 (CD18) were down-regulated in TIL and LPL with CD8+ cytotoxic phenotype, but not in those with CD4+ phenotype. CD8+ TIL expressed a slightly but significantly higher level of alphaLbeta2 than did CD8+ LPL. CD8+ LPL and CD8+ TIL consistently showed significantly decreased binding to purified ICAM-1, VCAM-1 and HT29 colon cancer cells as compared with CD8+ PBL. Although CD8+ TIL showed a slightly higher level of adhesion to these substrates than did CD8+ LPL, the level was much lower than that in PBL. The expression pattern and functional down-regulation of these integrins may be one of the reasons why TIL cannot eradicate the cancer cells in colorectal cancer.
Similar articles
-
Functional expression of beta1 and beta2 integrins on tumor infiltrating lymphocytes (TILs) in colorectal cancer.J Gastroenterol. 1999 Jun;34(3):327-33. doi: 10.1007/s005350050269. J Gastroenterol. 1999. PMID: 10433007
-
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3. doi: 10.1097/01.sla.0000247058.43243.7b. Ann Surg. 2006. PMID: 17122624 Free PMC article.
-
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.Gynecol Oncol. 2001 Jun;81(3):424-32. doi: 10.1006/gyno.2001.6200. Gynecol Oncol. 2001. PMID: 11371133
-
The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Eur J Surg Oncol. 2012. PMID: 22721580 Review.
-
Signaling defects in T lymphocytes of patients with malignancy.Cancer Immunol Immunother. 1999 Oct;48(7):346-52. doi: 10.1007/s002620050585. Cancer Immunol Immunother. 1999. PMID: 10501846 Free PMC article. Review.
Cited by
-
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Lab Invest. 2017 Jun;97(6):669-697. doi: 10.1038/labinvest.2017.25. Epub 2017 Mar 27. Lab Invest. 2017. PMID: 28346400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous